Calithera Biosciences, Inc. (CALA) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
343 OYSTER POINT BLVD #200 SOUTH SAN FRANCISCO, CA 94080 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 12/31/2022 Q4 | 9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 34,068 | 41,789 | 44,664 | 59,537 | 84,493 | 92,205 | |||
| Cash and cash equivalents | 34,068 | 41,789 | 44,664 | 59,537 | 84,493 | 92,205 | |||
| Receivables | 127 | 12 | 12 | ||||||
| Other undisclosed current assets | 629 | 1,035 | 2,478 | 1,915 | 1,829 | 1,776 | |||
| Total current assets: | 34,697 | 42,824 | 47,269 | 61,452 | 86,334 | 93,993 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 1,640 | 1,926 | 2,205 | 2,478 | 2,745 | 3,006 | |||
| Property, plant and equipment | 476 | 538 | 492 | 556 | 622 | 544 | |||
| Restricted cash and investments | 270 | 270 | 270 | 270 | 270 | 270 | |||
| Other noncurrent assets | 46 | ||||||||
| Total noncurrent assets: | 2,386 | 2,734 | 2,967 | 3,304 | 3,637 | 3,866 | |||
| TOTAL ASSETS: | 37,083 | 45,558 | 50,236 | 64,756 | 89,971 | 97,859 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 7,929 | 7,003 | 5,761 | 7,546 | 7,707 | 5,578 | |||
| Employee-related liabilities | ✕ | 3,167 | 2,700 | 2,146 | 3,283 | 3,874 | 3,283 | ||
| Accounts payable | 1,012 | 990 | 2,124 | 3,650 | 2,971 | 1,534 | |||
| Accrued liabilities | 3,750 | 3,313 | 1,491 | 613 | 862 | 761 | |||
| Other undisclosed current liabilities | 1,303 | 1,891 | 5,614 | 6,460 | 5,823 | 6,900 | |||
| Total current liabilities: | 9,232 | 8,894 | 11,375 | 14,006 | 13,530 | 12,478 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation: | 533 | 917 | 1,295 | 1,666 | 2,022 | 2,368 | |||
| Liabilities, other than long-term debt | |||||||||
| Operating lease, liability | 533 | 917 | 1,295 | 1,666 | 2,022 | 2,368 | |||
| Other undisclosed noncurrent liabilities | 397 | (421) | (1,295) | (1,666) | (2,022) | (2,368) | |||
| Total noncurrent liabilities: | 1,463 | 1,413 | 1,295 | 2,022 | 2,368 | ||||
| Total liabilities: | 10,695 | 10,307 | 12,670 | 15,672 | 15,552 | 14,846 | |||
| Temporary equity, carrying amount | 40,702 | 40,702 | |||||||
| Equity | |||||||||
| Equity, attributable to parent | 26,388 | 35,251 | (3,136) | 8,382 | 74,419 | 83,013 | |||
| Preferred stock | 22,342 | 22,342 | |||||||
| Common stock | 8 | 8 | 7 | 7 | |||||
| Additional paid in capital | 509,726 | 508,787 | 502,017 | 499,700 | 496,528 | 493,950 | |||
| Accumulated deficit | (505,680) | (495,878) | (505,161) | (491,326) | (422,116) | (410,944) | |||
| Total equity: | 26,388 | 35,251 | (3,136) | 8,382 | 74,419 | 83,013 | |||
| TOTAL LIABILITIES AND EQUITY: | 37,083 | 45,558 | 50,236 | 64,756 | 89,971 | 97,859 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 12/31/2022 Q4 | 9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 6,750 | 3,000 | ||||||
| Gross profit: | 6,750 | 3,000 | ||||||
| Operating expenses | (9,526) | (11,376) | (13,826) | (69,209) | (17,900) | (17,307) | ||
| Operating loss: | (9,526) | (11,376) | (13,826) | (69,209) | (11,150) | (14,307) | ||
| Nonoperating income (expense) (Other Nonoperating Income (Expense)) | (276) | 2,299 | ||||||
| Loss from continuing operations before equity method investments, income taxes: | (9,802) | (9,077) | (13,826) | (69,209) | (11,150) | (14,307) | ||
| Other undisclosed income from continuing operations before income taxes | 347 | |||||||
| Loss from continuing operations: | (9,802) | (9,077) | (13,826) | (68,862) | (11,150) | (14,307) | ||
| Loss before gain (loss) on sale of properties: | ✕ | (9,802) | (9,077) | (13,826) | (68,862) | (11,150) | (14,307) | |
| Other undisclosed net loss | (9) | (348) | ||||||
| Net loss: | (9,802) | (9,077) | (13,835) | (69,210) | (11,150) | (14,307) | ||
| Other undisclosed net loss attributable to parent | (22) | (4) | ||||||
| Net loss attributable to parent: | (9,802) | (9,077) | (13,835) | (69,210) | (11,172) | (14,311) | ||
| Undistributed earnings (loss) allocated to participating securities, basic | (1,362) | |||||||
| Other undisclosed net income available to common stockholders, basic | 18,360 | |||||||
| Net income (loss) available to common stockholders, basic: | (9,802) | 7,921 | (13,835) | (69,210) | (11,172) | (14,311) | ||
| Dilutive securities, effect on basic earnings per share | (16,998) | |||||||
| Net loss available to common stockholders, diluted: | (9,802) | (9,077) | (13,835) | (69,210) | (11,172) | (14,311) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 12/31/2022 Q4 | 9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (9,802) | (9,077) | (13,835) | (69,210) | (11,150) | (14,307) | ||
| Comprehensive loss: | (9,802) | (9,077) | (13,835) | (69,210) | (11,150) | (14,307) | ||
| Other undisclosed comprehensive loss, net of tax, attributable to parent | (22) | (4) | ||||||
| Comprehensive loss, net of tax, attributable to parent: | (9,802) | (9,077) | (13,835) | (69,210) | (11,172) | (14,311) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.